

# Subject Index

1S, 3R-ACPD, 230  
619C89  
cerebral focal ischemia and, 39  
increasing intravenous doses of, 324, 328

**A**cute ischemic stroke  
619C89 and, 324, 328  
lifarizine in, 317  
remacemide HCl and, 322  
Ro-01-6794/706 and, 249

Acute neurodegenerative processes,  
evaluating protection against, 50

Acute neuroprotection, adenosine and, 169

Adenosine, brain and, 163

Adenosine A<sub>2</sub> receptor, dopamine D<sub>2</sub>  
receptor and, 168

Adenosine receptor types, 164

Adhesion molecules, brain injury and, 65

Age dependence, dexamethasone and, 189

1-Aminocyclopropanecarboxylic acid  
(ACPC), 320

Animal model  
human model and, 60  
safety parameters in, 199

Antioxidant enzymes, free radicals and,  
183

Antioxidants, 116

Aptiganel hydrochloride (CNS 1102), 279

Assessment approaches, 59

**B**ehavior, hypoxic rats and, 34

Biologically based dose-response model,  
339

Biomarkers of neurotoxicity, 205

Blood pressure, CNS 1102 and, 287

Brain injury, TNF $\alpha$  and, 62

**C**alcitonin gene-related peptide,  
subarachnoid hemorrhage and, 299

Calcium, glucocorticoid receptors and, 134

Calcium antagonists, 119, 185

Calcium channel antagonists,  
depolarization and, 160

Calcium channels  
presynaptic, 214  
short-term regulation of, 119  
use-dependent blockers of, 210

Caloric reduction, oxidative brain damage  
and, 308

Cannabinoid, HU-211 as, 314

Cardiopulmonary bypass,  
neurophysiological test scores in,  
23

Carotid endarterectomy, 23

Catalase, 184

Catecholamines, glutamine-enhanced  
release of, 75

Cell culture  
1,4-dihydropyridine binding assay in,  
122  
disadvantage of, 111

Central nervous system, TNF $\alpha$  and, 63

Cerebral blood flow  
adenosine and, 163  
CNS 1102 and, 280  
dexamethasone and, 182

Cerebral circulation, 334

Cerebral focal ischemia, 619C89 and, 39

Cerebral hypoxic injury, 31

Cerebrovascular effects, CNS 1102, 280

Channel classification and regulation, 120

Chronic administration, adenosine-based  
therapies and, 170

Clinical pharmacology, CNS 1102, 279

Clinical potential for neuroprotective  
agents, 1

Clinical syndromes, 26

CNS 1102  
cerebral hemodynamic and metabolic  
effects of, 332  
clinical pharmacology of, 279, 336  
CNS 1237, use-dependent channel block  
and, 219

Cocaine dependence, nimodipine and, 150

“Code Stroke” alert system, 2

Corticosterone, adrenal cortical hormone  
receptors and, 134

Corticosterone levels, variability of, 139

Corticosterone receptors types I and II,  
135

**D**dendritic atrophy, nimodipine and, 312

2-Deoxyglucose, dexamethasone and, 189

Depolarization, 125

Dexamethasone, neonatal hypoxic-  
ischemic brain damage and, 179

Dextrorphan HCl, safety of, 249

Diffuse axonal injury, 263

1,4-Dihydropyridines, binding of, 120

Dopamine D<sub>2</sub> receptor, adenosine A<sub>2</sub>  
receptor and, 168

Doppler ultrasound, 280

Dorsal root ganglion, radical scavengers  
and, 111

Dose-response models, 203

**E**lectroencephalogram (EG), recording  
procedures of, 145

Electrophysiology, use-dependent channel  
block and, 216

Energy disrupters, 116  
Energy metabolism, 32  
Energy repletion, neuroprotective effects of, 104  
Epilepsy  
  NMDA antagonists in, 12  
  remacemide and, 277  
Event-related potential, substance abusers and, 152  
Excitatory amino acid  
  severe head trauma and, 290  
  excessive release of, 262  
Excitotoxic effects, glutamate and, 290  
Excitotoxic mechanisms, acute subdural hematoma and, 265  
Excitotoxic neuronal death, CNS 1102 and, 336  
Excitotoxicity, 98  
  neurodegenerative diseases and, 100

**F**asting, dexamethasone and, 187  
Fluid percussion injury, 264  
Flunarizine, dexamethasone and, 185  
Focal cerebral ischemia  
  models of, 242  
  prophylactic neuroprotection in, 4, 21  
  remacemide HCl and, 322  
  small animal model of, 301  
Free fatty acids, 33  
Free radical scavengers  
  neuroprotective effects of, 102  
  side effects and safety of, 117  
Free radicals  
  adenosine and, 171  
  antioxidant enzymes and, 183

**G**proteins, adenosine and, 172  
Gamma-aminobutyric acid (GABA), visual spatial learning in rats and, 4  
Ganglioside GM<sub>1</sub>  
  methamphetamine-induced neurotoxicity and, 311  
  perinatal brain injury and, 304  
GH<sub>4</sub>C<sub>1</sub> cells, 120  
Glia, effects of glutamine on, 78  
Global cerebral ischemia  
  remacemide HCl and, 322  
  models of, 238  
Glucocorticoid, 180  
  P3B and, 161  
Glucose utilization, dexamethasone effects on, 188  
Glutamate  
  CNS and, 279  
  glial cells and, 79  
  hypocapnia and, 86  
  putative excitotoxic effects of, 290  
  use-dependent blockers controlling, 210  
Glutamate antagonists, strategies for neuroprotection with, 272  
Glutamate release, 619C89 and, 328  
Glutamate uptake, endogenous adenosine and, 166  
Glutamine-enhanced glutamate release, 72  
Glycine  
  hypocapnia and, 86  
  NMDA receptor and, 320

**H**Hallucinations, 619C89 and, 329  
Head injury  
  CNS 1102 and, 332  
  EAA release and, 290  
  glutamate antagonist in treatment of, 262  
Hippocampal slices, glutamate from, 75  
Hippocampus  
  adrenal cortical hormone receptors of, 134  
  hypocapnia and, 86  
  quantitative histological evaluation of neurotoxic damage in, 303  
  trimethyltin and, 54  
HU-211, neuroprotective activity of, 314  
Huntington's disease, 14  
  remacemide HCl and, 245  
Hyperglycemia, dexamethasone and, 186  
Hyperthermia, MK-801 and, 7  
Hyperventilation, brain lactate and, 86  
Hypocapnia, extracellular glutamate and glycine and, 86  
Hypotension, dextrophorphan and, 254  
Hypothermia  
  hypoxic-ischemic damage and, 182  
  ischemia/reperfusion injury and, 98  
  methamphetamine neurotoxicity and, 338  
Hypoxia, intact dorsal root ganglion, 111  
Hypoxia-ischemia, dexamethasone and, 179  
Hypoxic depolarization, adenosine and, 166  
Hypoxic-ischemic brain injury, role of growth factors after, 306

**I**mmunohistochemistry of neurotoxicity biomarkers, 50  
Infarct volume, 619C89 and, 43  
Infarction, hypoxia-ischemia and, 181  
Inflammation, TNF $\alpha$  and, 62  
Insulin-like growth factor 1, hypoxic-ischemic brain injury and, 306  
Intracranial pressure, EAA release and, 294  
Ion conductances, adenosine and, 167

Ischemia, glutamate release blockers and, 212  
Ischemic damage, hippocampal, 263  
Ischemic stroke, multicenter clinical trials and, 2

**K**ainate, glutamate levels and, 78  
Kynurene, glutamate levels and, 78

**L**-AP4, 230  
L-CCG1, 230  
L-channels, 120  
L-SOP, 230  
Lactate, brain, 86  
Lifarizine, acute ischemic stroke and, 317  
Limbic seizures, metabotropic glutamate receptor agonist-mediated, 230

**M**agnesium, 196  
Magnesium sulfate, acute stroke and, 315  
Mechanism, 98  
Memory retention, nimodipine and, 312  
Metabotropic glutamate receptors, 230  
Methamphetamine, glutamate levels and, 78  
Methamphetamine neurotoxicity, hypothermia and, 338  
Methemoglobinemia, 136  
Microdialysis, 291  
Middle cerebral artery occlusion (MCAO), use-dependent channel block and, 218  
Middle cerebral artery occlusion model of focal ischemia, 619C89 and, 39  
MK-801, S-PBN and, 104  
Morphometric studies, experimental design of, 47  
Muscarinic receptors, 125

**N**-channels, 120  
Neonatal brain damage, dexamethasone and, 179  
Nerve growth factors, dexamethasone and, 196  
Neurodegeneration  
adenosine A<sub>2</sub> receptors and, 167  
excitotoxic hypothesis and, 268  
Neurodegenerative disease  
animal models of, 101  
EAA toxicity and, 12  
Neurological deficit, 619C89 and, 45  
Neuroprotection  
619C89 and, 42  
radical scavengers and, 111  
Neuroprotection regimen, prophylactic pharmacologic, 22

Neurotoxicity  
assessing human, 198  
NMDA antagonists and, 268  
Neurotoxicity endpoints, 200  
Neurotransmitter release, adenosine analogues and, 165  
Neurotrauma, CGS 19755 and, 272  
Nimodipine  
auditory rare event monitoring task and, 153  
cerebral blood flow and, 334  
EEG of substance abusers and, 143, 152  
neocortical dendritic atrophy and, 312  
Nitric oxide, NMDA receptors and, 310  
NMDA (*N*-methyl-D-aspartate)  
depolarization in rat hippocampal slices and, 237  
ischemia and, 3

**N**MDA antagonist  
head trauma and, 298  
head-injured patients and, 262  
magnesium as, 315  
remacemide and, 248, 322  
safety and, 249

NMDA channel blocker, CNS 1102 as, 273

**N**MDA receptor  
adenosine and, 164  
amphetamine's interactions with, 309  
CNS 1102 and, 279, 336  
magnesium and, 315  
Parkinson's disease and, 327  
sensitization and desensitization of, 320

Noncompetitive antagonist, CNS 1102 as, 287

Neuroprotective agents, clinical potential for use of, 1

**O**xidative brain damage, caloric reduction and, 308  
Oxidative stress, hyperthermia and, 98  
Oxygen radicals, dorsal root ganglion hypoxia model and, 111

**P**-channels, 120  
P3, substance abusers and, 152  
Parkinson's disease  
models of, 244  
NMDA antagonists in, 14  
NMDA receptor participation in, 327  
Pathophysiology and therapeutic intervention, 304  
Periischemic period, hypcapnia and, 86  
Perinatal brain injury, 304  
Pharmacokinetics, dextrorphan, 255  
Phospholipase A<sub>2</sub>, 341  
Placebo effects, 138  
Placental insufficiency, 28

Polymorphonuclear leukocytes, brain injury and, 64

Principal components analysis, ERP and, 154

Prophylactic pharmacologic neuroprotection, focal cerebral ischemia and, 21

Protein kinase C, 125

Protooncogene expression, reactive oxygen species and, 340

**Q** Quantitative histological evaluation, neuroprotective compounds and, 47

**R** Rapid superfusion system,  $^3\text{H}$ -glutamate release and, 221

Reactive oxygen species, protooncogene expression and, 340

Reflex sympathetic dystrophy, C fiber activity in, 15

Remacemide hydrochloride acute ischemic stroke and, 322 mechanism of action of, 236 Sprague-Dawley rats and, 330

Risk assessment biologically based dose-response model for, 339 biomarkers and, 209 strategies of, 198

Ro-01-6794/706, safety of, 249

**S** S-PBN, free radical generation and, 102

Safety and tolerability, dextrorphan and, 251

Safety evaluation programs, novel therapeutics and, 319

Safety-factor approach, 201

Silver impregnation of degenerative processes, 50

Small animal model, focal cerebral ischemia, 301

Sodium channels neuronal voltage-activated, 213 use-dependent blockers of, 210

Spinal cord injury, methylprednisolone in, 9

Spontaneously hypertensive rats, 619C89 and, 40

Staurosporine, 125

Steriology, 49

Stress, methemoglobin production and, 136

Striatal slices, glutamate from, 75

Stroke CGS 19755 and, 272 CNS 1102 and, 287 magnesium and, 315

Stroke rate, annual, 22

Subarachnoid hemorrhage calcitonin gene-related peptide and, 299 models of, 243 vasospasm in, 6

Substance abuse EEG activity in, 14 nimodipine and, 143, 152

Superoxide, 184

Surgical retraction injury, 11

Systolic blood pressure, dextrorphan and, 258

**T**  $\text{T}$ -channels, 120

Taurine, release of, from cultured glia, 78

Tetrodotoxin, use-dependent channel block and, 219

Therapeutics, novel, safety evaluation programs for, 319

Transcranial Doppler (TCD) ultrasound, 280

Transforming growth factor  $\beta_1$  (TGF $\beta_1$ ), hypoxic-ischemic brain injury and, 306

Traumatic brain injury, EAA antagonist therapy in, 6

Trimethyltin, axon terminal degeneration and, 54

Tumor necrosis factor alpha (TNF $\alpha$ ), brain injury and inflammation and, 62

**U** U-74689F, dexamethasone and, 185

Use-dependent blockers, 210

**V** Verapamil, cerebral blood flow and, 334

Veratridine, 126

Vitamin E, methamphetamine-induced neurotoxicity and, 311

Voltage sensitive sodium channels, 39

Volunteers, healthy 619C89 and, 324 CNS 1102 in, 287, 337

**W** "Weibel's Bible," 47

## Index of Contributors

**A**lbers, G. W., 249-261

Ali, S. F., 311, 338

Arvin, B., 62-71

Atkinson, R., 249-261

**B**amford, J., 317-318

Bär, P. R., 111-115

Barone, F. C., 62-71

Beal, M. F., 100-110

Beenhakker, M., 163-178

Beilharz, E., 306-307

Bell, B. A., 299-300, 301-302

Berlove, D., 210-229

Biegong, A., 314

Binienda, Z., 28-38

Borrelli, A. R., 236-247

Bowyer, J. F., 72-85, 309-310, 338

Bredesen, D. E., 340

Bullock, R., 262-271, 272-278, 290-297

Burton, D., 312-313

**C**arter, M. F., 163-178

Case, K. R., 330-331

Cavagnaro, J. A., 319

Chen, J., 210-229

Choi, K. T., 86-97

Chung, J. K., 86-97

Clifton, G., 332-333

Cregan, E. F., 236-247

Curry, S., 330-331

**D**aly, D., 210-229

Davies, D. L., 72-85

Durant, G. J., 210-229

Dvorak, R., 312-313

**E**isman, M. S., 330-331

**F**euerstein, G. Z., 62-71

Fischer, J. B., 210-229

Forster, M. J., 308

Fossum, L. H., 320-321

**G**aylor, D. W., 198-208, 339

George, C. F., 328-329

Gluckman, P., 304-305, 306-307

Goldin, S. M., 210-229

Graham, S. H., 210-229

Griffey, K. I., 230-235

Grosset, D. G., 279-289, 336-337

Guan, J., 306-307

Gunn, A., 304-305

Guo, X., 143-151, 152-159

**H**amilton, S. J. C., 328-329

Herning, R. I., 143-151, 152-159

Hobbiger, S., 324-326, 328-329

Holland, J. P., 301-302

Holson, R. R., 338

Holt, W. F., 210-229

Hoover, L., 312-313

Hu, L-Y., 210-229

Hussein, Z., 324-326

**I**saacson, R. L., 134-142

**J**acobson, K. A., 163-178

Johnston, B., 304-305

Jonas, S., 21-25

**K**atz, P., 249-261

Kelley, R. E., 249-261

Kertesz, A., 317-318

Kim, H. K., 86-97

Knapp, A. G., 210-229

Kulkarni, S. K., 327

Kuntz, N., 312-313

Kwak, C. S., 86-97

**L**al, H., 308

Lamb, R. J., 324-326

Lange, W. R., 143-151, 152-159

Leach, M. J., 39-46

Lees, K. R., 279-289, 315-316, 317-318, 322-323, 328-329, 336-337

Lehr, L., 249-261

Lesko, L. M., 249-261

Lin, R. C-S., 163-178

Lipe, G. W., 72-85

Liu, J., 119-133

Liu, S., 319

Lunnon, M. W., 328-329

**M**agar, S., 210-229

Magni, G., 249-261

Mahmood, N. A., 330-331

Mallard, C., 304-305

Margolin, L. D., 210-229

Marks, K., 304-305

Marler, M. R., 330-331

Marmarou, A., 290-297

Matthews, J. C., 72-85

McCarthy, D. J., 330-331

McNeill, H., 306-307

Mercer, A. J., 324-326

Mervis, R. F., 312-313

Miller, O., 306-307

Modi, M., 249-261

Muir, K. W., 279-289, 315-316, 322-323,

328-329, 336-337

Myseros, J. S., 262-271, 290-297

**N**eville, L. F., 62-71  
Newport, G. D., 338

**P**almer, G. C., 236-247  
Paul, K., 249-261  
Perlman, M. E., 210-229  
Pitman, V., 249-261  
Posner, J., 324-326  
Pryse-Phillips, W., 317-318

**R**ae, J., 249-261  
Reddy, N. L., 210-229  
Rosenbaum, D. M., 249-261  
Rutledge, A., 119-133

**S**arafian, T., 340  
Scallet, A. C., 47-58, 72-85, 303  
Schoepp, D. D., 230-235  
Schulz, J. B., 100-110  
Sharma, R., 210-229  
Sirimanne, E., 306-307  
Skolnick, P., 320-321  
Slikker, W., Jr., xi, 198-208, 338, 339  
Sohal, R. S., 308  
Solomon, P. R., 312-313  
Squire, I. B., 317-318  
Stewart, L., 332-333

Subbarao, K., 210-229  
Swan, J. H., 39-46

**T**an, W., 304-305  
Tandon, R., 312-313  
Teasdale, G. M., 332-333  
Tizzano, J. P., 230-235  
Trembly, B., xi, 1-20  
Triggle, D. J., 119-133  
Tuor, U. I., 179-195

**V**arner, J. A., 134-142  
Verity, M. A., 340, 341  
Verma, A., 327  
von Lubitz, D. K. J. E., 163-178

**W**agstaff, A., 332-333  
Weinstein, G. B., 334-335  
Willett, F., 236-247  
Williams, C., 304-305, 306-307  
Wood, M. S., 312-313  
Woodward, J. J., 290-297

**Y**oo, K., 249-261  
Young, H. F., 290-297  
**Z**auner, A., 290-297

